menaquinone-6 and Pain

menaquinone-6 has been researched along with Pain* in 2 studies

Trials

1 trial(s) available for menaquinone-6 and Pain

Article	Year
Health state utility values and patient-reported outcomes before and after vertebral and non-vertebral fractures in an osteoporosis clinical trial. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2017, Volume: 28, Issue:6 We assessed the health state utility value (HSUV) reductions associated with vertebral fractures using data collected in the Japanese Osteoporosis Intervention Trial-03 (JOINT-03). Our analysis revealed that assessment of HSUVs after morphometric vertebral fracture is important to capture the burden of vertebral fractures.. Evaluation of the HSUV after fracture is important to calculate the quality-adjusted life years (QALYs) of osteoporosis patients, which is essential information in the context of health economic evaluation.. JOINT-03 study patients were aged ≥65 years and treated with risedronate and vitamin K. Among 2922 follow-up HSUVs, 201 HSUVs were categorized as HSUVs that were observed after incident vertebral fractures on X-ray films. The median time from the detection of an incident vertebral fracture until the EQ-5D assessment was 53 days (25th percentile, 0 day; 75th percentile, 357 days). The impact of incident vertebral fractures on HSUVs was quantified as -0.03. Among the five health profile domains on the EQ-5D, an incident vertebral fracture had significant effects on anxiety/depression, self-care, and usual activities.. The results suggest that incident morphometric vertebral fracture was associated with impairment of the HSUV for patients with osteoporosis not only immediately but also several months after the fracture. Topics: Activities of Daily Living; Aged; Aged, 80 and over; Bone Density Conservation Agents; Drug Therapy, Combination; Female; Humans; Japan; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Pain; Pain Measurement; Patient Reported Outcome Measures; Quality-Adjusted Life Years; Risedronic Acid; Spinal Fractures; Vitamin K 2	2017

Article

Year

Health state utility values and patient-reported outcomes before and after vertebral and non-vertebral fractures in an osteoporosis clinical trial.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2017, Volume: 28, Issue:6

We assessed the health state utility value (HSUV) reductions associated with vertebral fractures using data collected in the Japanese Osteoporosis Intervention Trial-03 (JOINT-03). Our analysis revealed that assessment of HSUVs after morphometric vertebral fracture is important to capture the burden of vertebral fractures.. Evaluation of the HSUV after fracture is important to calculate the quality-adjusted life years (QALYs) of osteoporosis patients, which is essential information in the context of health economic evaluation.. JOINT-03 study patients were aged ≥65 years and treated with risedronate and vitamin K. Among 2922 follow-up HSUVs, 201 HSUVs were categorized as HSUVs that were observed after incident vertebral fractures on X-ray films. The median time from the detection of an incident vertebral fracture until the EQ-5D assessment was 53 days (25th percentile, 0 day; 75th percentile, 357 days). The impact of incident vertebral fractures on HSUVs was quantified as -0.03. Among the five health profile domains on the EQ-5D, an incident vertebral fracture had significant effects on anxiety/depression, self-care, and usual activities.. The results suggest that incident morphometric vertebral fracture was associated with impairment of the HSUV for patients with osteoporosis not only immediately but also several months after the fracture.

Topics: Activities of Daily Living; Aged; Aged, 80 and over; Bone Density Conservation Agents; Drug Therapy, Combination; Female; Humans; Japan; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Pain; Pain Measurement; Patient Reported Outcome Measures; Quality-Adjusted Life Years; Risedronic Acid; Spinal Fractures; Vitamin K 2

2017

Other Studies

1 other study(ies) available for menaquinone-6 and Pain

Article	Year
Antinociceptive effect of vitamin K2 (menatetrenone) in diabetic mice. Japanese journal of pharmacology, 2001, Volume: 85, Issue:3 The antinociceptive effect of vitamin K2 (menatetrenone) in diabetic mice was examined using a tail-pressure test. Intraperitoneal injection of menatetrenone (10-100 mg/kg) produced a dose-dependent increase in the nociceptive threshold in diabetic mice. There was no significant difference between non-diabetic and diabetic mice in the menatetrenone-induced changes in the nociceptive threshold. The results suggest the therapeutical usefulness of menatetrenone for treating painful diabetic neuropathy and osteoporosis. Topics: Analgesics; Animals; Diabetic Neuropathies; Male; Mice; Mice, Inbred ICR; Pain; Pain Measurement; Tail; Vitamin K; Vitamin K 2	2001

Article

Year

Antinociceptive effect of vitamin K2 (menatetrenone) in diabetic mice.

Japanese journal of pharmacology, 2001, Volume: 85, Issue:3

The antinociceptive effect of vitamin K2 (menatetrenone) in diabetic mice was examined using a tail-pressure test. Intraperitoneal injection of menatetrenone (10-100 mg/kg) produced a dose-dependent increase in the nociceptive threshold in diabetic mice. There was no significant difference between non-diabetic and diabetic mice in the menatetrenone-induced changes in the nociceptive threshold. The results suggest the therapeutical usefulness of menatetrenone for treating painful diabetic neuropathy and osteoporosis.

Topics: Analgesics; Animals; Diabetic Neuropathies; Male; Mice; Mice, Inbred ICR; Pain; Pain Measurement; Tail; Vitamin K; Vitamin K 2

2001